ReviewJournal of clinical medicine research2017
Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.
Review in Journal of clinical medicine research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2026Pooled it
- The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies.African health sciences · 2021Pooled it
- Dapagliflozin's impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial.Diabetologia · 2025Trial
- Computational discovery of fenugreek-paitan-turmeric (FPT) bioactive compounds targeting SGLT2 and DPP-4 for glucose homeostasis regulation.Journal of Taibah University Medical Sciences · 2026Article
- The Association of SGLT2i vs DPP4i on Fracture: A Cohort Study in Veterans with Diabetes.American journal of medicine open · 2025Article
- Recent Progress and Perspectives in Sodium-Glucose Co-transporter 1/2 Inhibitors.Mini reviews in medicinal chemistry · 2025Review
- Multi-dimensional roles of sodium-glucose cotransporter 2 inhibitors: beyond hypoglycemic and cardiorenal protection.Frontiers in endocrinology · 2025Review
- In silico analysis of Rutin and Morin against diabetes-associated molecular targets.In silico pharmacology · 2025Article
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases.ACS pharmacology & translational science · 2024Review
- Comparison of SGLT1, SGLT2, and Dual Inhibitor biological activity in treating Type 2 Diabetes Mellitus.Advanced therapeutics · 2023Article
- Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.Cardiovascular diabetology · 2023 · on this mapArticle
- Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?Nature cardiovascular research · 2023Article
- Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches.Frontiers in pharmacology · 2023Article
- Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes.PloS one · 2023Article
- Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling.BMC medicine · 2022Article
- Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment.Pharmacological research · 2022Review
- SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist.Frontiers in nephrology · 2022Review
- An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is).Diabetes, metabolic syndrome and obesity : targets and therapy · 2021 · on this mapReview
- SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence.Journal of diabetes research · 2021Review
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.Cardiovascular diabetology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that improve glycemic control by inhibiting reabsorption of glucose filtered through the renal glomerulus. Use of drugs in this class has increased because of their effect of decreasing body weight and a low risk for hypoglycemia, in addition to a relatively strong glucose-lowering effect. SGLT2 inhibitors such as canagliflozin and sotagliflozin (a SGLT1/SGLT2 dual inhibitor) also have a mild or moderate intestinal and renal SGLT1 inhibitory effect because of their relatively weak selectivity for SGLT2 over SGLT1. Recent evidence shows that these SGLT2 inhibitors with low SGLT2/SGLT1 selectivity elevate the level of circulating glucagon like peptide-1 (GLP-1), an incretin hormone that promotes insulin secretion in pancreatic β cells. This effect probably occurs partly via inhibition of intestinal SGLT1, and the elevation of active GLP-1 levels is especially apparent when these drugs are co-administered with dipeptidyl peptidase 4 (DPP4) inhibitors. These findings suggest that a combination of canagliflozin or sotagliflozin and a DPP4 inhibitor can provide a beneficial effect associated with elevation of circulating active GLP-1 and may serve as a treatment for patients with type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.